IMHO it is a startegic move initiated by Dr. JL. W
Post# of 148166
He probably started the compasenate use song again with the FDA, being shut down with the SOC being Remdesivier for the time being.
Not wanting to wait further (until mid June for the results of the P2) and seing people die in the meantime the strategic move to challenge the SOC is brilliant.
Being a phase 3 has the advantage that if the FDA declines it...... they can later not easily ask for a P3 (mild to moderate) for Leronlimab without looking totally rediculous.
Greetings from Germany
baggo-mh